178 related articles for article (PubMed ID: 8099689)
1. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson's disease.
Limousin P; Pollak P; Gervason-Tournier CL; Hommel M; Perret JE
Lancet; 1993 Jun; 341(8860):1605. PubMed ID: 8099689
[No Abstract] [Full Text] [Related]
2. Tolcapone: a review of its use in the management of Parkinson's disease.
Keating GM; Lyseng-Williamson KA
CNS Drugs; 2005; 19(2):165-84. PubMed ID: 15697329
[TBL] [Abstract][Full Text] [Related]
3. Tolcapone in the management of Parkinson's disease.
Leegwater-Kim J; Waters C
Expert Opin Pharmacother; 2006 Nov; 7(16):2263-70. PubMed ID: 17059382
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson's disease.
Baas H; Zehrden F; Selzer R; Kohnen R; Loetsch J; Harder S
Clin Pharmacokinet; 2001; 40(5):383-93. PubMed ID: 11432539
[TBL] [Abstract][Full Text] [Related]
5. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.
Limousin P; Pollak P; Pfefen JP; Tournier-Gervason CL; Dubuis R; Perret JE
Clin Neuropharmacol; 1995 Jun; 18(3):258-65. PubMed ID: 8635184
[TBL] [Abstract][Full Text] [Related]
6. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease.
Yamamoto M; Yokochi M; Kuno S; Hattori Y; Tsukamoto Y; Narabayashi H; Tohgi H; Mizuno Y; Kowa H; Yanagisawa N; Kanazawa I
J Neural Transm (Vienna); 1997; 104(2-3):229-36. PubMed ID: 9203084
[TBL] [Abstract][Full Text] [Related]
7. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.
Roberts JW; Cora-Locatelli G; Bravi D; Amantea MA; Mouradian MM; Chase TN
Neurology; 1993 Dec; 43(12):2685-8. PubMed ID: 8255478
[TBL] [Abstract][Full Text] [Related]
8. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
J Neurol Neurosurg Psychiatry; 1997 Oct; 63(4):421-8. PubMed ID: 9343116
[TBL] [Abstract][Full Text] [Related]
9. Tolcapone, a selective catechol-O-methyltransferase inhibitor for treatment of Parkinson's disease.
Guay DR
Pharmacotherapy; 1999 Jan; 19(1):6-20. PubMed ID: 9917075
[TBL] [Abstract][Full Text] [Related]
10. Influence of COMT inhibition on levodopa pharmacology and therapy.
Goetz CG
Neurology; 1998 May; 50(5 Suppl 5):S26-30. PubMed ID: 9591519
[TBL] [Abstract][Full Text] [Related]
11. The relationship between COMT genotype and the clinical effectiveness of tolcapone, a COMT inhibitor, in patients with Parkinson's disease.
Chong DJ; Suchowersky O; Szumlanski C; Weinshilboum RM; Brant R; Campbell NR
Clin Neuropharmacol; 2000; 23(3):143-8. PubMed ID: 10895397
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone.
Jorga K; Banken L; Fotteler B; Snell P; Steimer JL
Clin Pharmacol Ther; 2000 Jun; 67(6):610-20. PubMed ID: 10872643
[TBL] [Abstract][Full Text] [Related]
13. Utility of tolcapone in fluctuating Parkinson's disease.
Stocchi F; De Pandis MF
Clin Interv Aging; 2006; 1(4):317-25. PubMed ID: 18046910
[TBL] [Abstract][Full Text] [Related]
14. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
[TBL] [Abstract][Full Text] [Related]
15. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
Sabaté M; Bosch A; Pedrós C; Figueras A
Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
[No Abstract] [Full Text] [Related]
16. New approaches to the treatment of age-related brain disorders.
Da Prada M
Can J Neurol Sci; 1991 Aug; 18(3 Suppl):384-6. PubMed ID: 1933685
[TBL] [Abstract][Full Text] [Related]
17. Extending levodopa action: COMT inhibition.
Martínez-Martín P; O'Brien CF
Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
[TBL] [Abstract][Full Text] [Related]
18. COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.
Oechsner M; Buhmann C; Strauss J; Stuerenburg HJ
J Neural Transm (Vienna); 2002; 109(1):69-75. PubMed ID: 11793163
[TBL] [Abstract][Full Text] [Related]
19. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
Jorga KM
Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
